RESEARCH ARTICLE

Leucine coingestion augments the muscle protein synthetic response to the ingestion of 15 g of protein following resistance exercise in older men

Andrew M. Holwerda,1,4 Kevin J. M. Paulussen,1 Maarten Overkamp,1 Joy P. B. Goessens,1 Irene-Fleur Kramer,1 Will K. W. H. Wodzig,6 Lex B. Verdijk,1,4 Lisette C. P. G. M. de Groot,3,4 and Luc J. C. van Loon1,4

1NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, The Netherlands; 2Central Diagnostic Laboratory, Maastricht University Medical Centre, Maastricht, The Netherlands; 3Department of Human Nutrition, Wageningen University, Wageningen, The Netherlands; and 4Top Institute Food and Nutrition (TIFN), Wageningen, The Netherlands

Submitted 2 February 2019; accepted in final form 19 May 2019

INTRODUCTION

The age-related decline in skeletal muscle mass and strength, termed sarcopenia, is accompanied by impairments in functional capacity and an increased risk of developing chronic metabolic diseases (4). Whereas basal muscle protein synthesis and breakdown rates appear to be unaffected by age (33), the muscle protein synthetic response to the main anabolic stimuli, namely food intake and physical activity, seems to be blunted in older individuals (47). This anabolic resistance is now considered a central factor contributing to the progression of sarcopenia.

A single session of resistance-type exercise strongly increases muscle protein synthesis rates (36) and therefore represents an effective strategy to compensate for anabolic resistance. For older individuals, ingestion of more than 20 g of protein is required to augment postexercise muscle protein synthesis rates (10, 36, 53). Older individuals possess the capacity to further increase the postexercise muscle protein synthetic response by ingesting larger protein doses, with the ingestion of 40 g of protein further enhancing the muscle protein synthetic response (53, 54). However, older individuals seldom consume 40 g of protein in a single meal (40, 41). Therefore, research is warranted to determine nutritional strategies that can augment the muscle protein synthetic response to ingestion of small(er) amounts of protein during recovery from resistance-type exercise in older adults.

Leucine has been established as one of the amino acids with greater anabolic properties due to its ability to stimulate mammalian target of rapamycin complex 1 (mTORC1) activity to phosphorylate key anabolic signaling proteins (i.e., S6K1) in skeletal muscle tissue (3, 17). Previous work has demonstrated that coingestion of free leucine augments the muscle protein synthetic response to protein or amino acid ingestion in older individuals at rest (7, 9, 12, 13, 48) and after a single bout of resistance-type exercise (2, 7, 9, 12, 13). It has also been demonstrated that leucine coingestes with main meals augments the integrated muscle protein synthetic response to resistance-type exercise assessed over multiple days (30). However, as leucine also stimulates splanchnic tissue protein synthesis rates (29, 39), it could be speculated that free leucine coingestion stimulates the uptake and incorporation of dietary protein-derived amino acids in the splanchnic tissues, thereby attenuating the postprandial release of dietary protein-derived amino acids.
amino acids in the circulation. It remains to be established whether this would preclude the impact of free leucine coingestion to further increase postexercise muscle protein synthesis rates. In short, it remains unclear whether or not free leucine coingestion impacts postprandial protein handling following the ingestion of a small amount of protein during postexercise recovery in older individuals. Therefore, in the present study, we assessed postprandial protein handling and the muscle protein synthetic response following ingestion of a single 15-g bolus of protein with or without additional free leucine (1.5 g) during recovery from a single bout of resistance-type exercise in older individuals.

We hypothesized that coingestion of 1.5 g of free leucine with a single bolus of 15 g of protein attenuates the postprandial release of protein-derived amino acids in the circulation compared with the ingestion of 15 g of protein. Furthermore, we hypothesized that, despite a potential attenuated rise in postprandial plasma amino acid availability, free leucine coingestion will further increase postexercise muscle protein synthesis rates and allow for a greater incorporation of the available dietary protein-derived amino acids into myofibrillar protein. To test our hypothesis, we selected 24 healthy older (67 ± 1 yr) men who ingested 15 g of protein with or without 1.5 g of free leucine during recovery from a single bout of resistance-type exercise. By combining the ingestion of specifically produced intrinsically L-[1-13C]phenylalanine- and L-[1-15N]leucine-labeled milk protein concentrate with the administration of primed continuous infusions of L-[ring-2H5]phenylalanine, L-[1-13C]leucine, and L-[ring-2H3]tyrosine, we were able to assess protein digestion and amino acid absorption kinetics, the increase in muscle protein synthesis rate, and the postprandial incorporation of dietary protein-derived amino acids during recovery from exercise in older individuals.

MATERIALS AND METHODS

Subjects. A total of 24 healthy, normoglycemic, older men (67 ± 1 yr) were selected to participate in the present study. Subjects’ characteristics are presented in Table 1. Subjects were randomly assigned to ingest either 15 g of protein (15G: n = 12) or 15 g of protein with 1.5 g of crystalline free leucine (15G + LEU; n = 12) in a double-blind fashion after completing a single bout of whole body resistance-type exercise. Randomization was performed by an independent researcher, who created a table in Excel (Microsoft) using the random number generator function, which was coupled to the different beverages before sorting the number column in order of low to high. The independent researcher also prepared and masked the test beverages on the test day. All subjects were informed of the nature and possible risks of the experimental procedures before giving written informed consent was obtained. The study was approved by the Medical Ethics Committee of the Maastricht University Medical Centre, The Netherlands (METC 14-3-052) and conformed to standards for the use of human subjects in research as outlined in the most recent version of the Helsinki Declaration. All participants provided written informed consent before participation. This study is part of a greater project, which was registered at The Netherlands Trial Registry as NTR4492. Data from the 15G group was published previously as part of a protein dose-response study conducted in parallel within the same project (22).

Pretesting. Participants arrived at the laboratory at 0830 by car or public transportation in an overnight-fasted state. Upon arrival, body weight, body composition, and bone mineral content were measured with dual-energy X-ray absorptiometry (DEXA, Discovery A; Hologic, Bedford, MA). Thereafter, all participants performed an oral glucose tolerance test (OGTT). Plasma glucose and insulin concentrations were measured to determine oral glucose intolerance and/or the presence of type 2 diabetes according to 2006 American Diabetes Association guidelines (1). All subjects were screened on medical issues and excluded if any gastrointestinal, neurological, or renal diseases were present.

Subjects were cleared to perform resistance-type exercise by a cardiologist, who examined electrocardiograms (ECG) measured at rest and during submaximal cycling (performed at 70% of age-predicted heart rate maximum). The subjects were then familiarized with the exercise equipment and physical activity protocol. Subjects first performed a 10-min cycling warm-up at 70% of their age-predicted heart rate maximum before completing an estimation of their one-repetition maximum (1RM) on leg press and leg extension exercises by using the multiple repetitions testing procedure (28). For each exercise, subjects performed 10 submaximal repetitions to warm up and become familiarized with the equipment and to have lifting technique critiqued and corrected. Subjects then performed sets at progressively increasing loads until failing to complete a valid repetition, judged by their inability to complete the full range of motion for an exercise. Ideally, subjects failed within 3–6 repetitions during the last and heaviest set. A 2-min resting period between subsequent attempts was allowed. The pretesting and experimental trials were separated by a period of at least 7 days.

Diet and physical activity. All volunteers were instructed to refrain from any exhaustive physical activity and to keep their diet as consistent as possible 72 h before the trial. Subjects filled in dietary records for 48 h immediately before the experimental trial. Subjects consumed 8.6 ± 0.5 MJ/day on average, with 47 ± 1 energy% (En%) as carbohydrate, 33 ± 1 En% as fat, and 18 ± 1 En% as protein. Dietary protein intake averaged 1.1 ± 0.1 g/kg body wt. On the evening before the experiment, all subjects consumed a standardized meal (22.0 ± 0.6 kJ/kg body wt consisting of 55 En% as carbohydrate, 20 En% as protein, and 25 En% as fat).

Experimental protocol. At 0800, participants reported to the laboratory in a fasted and rested state and had Teflon catheters inserted into the antecubital veins of one arm and the top of the opposite hand. At 0830 (t = −150 min), and a background blood sample was taken before the initiation of the tracer infusion protocol. The plasma and intracellular phenylalanine and leucine pools were primed with a single intravenous dose (priming dose) of L-[ring-2H5]phenylalanine.

Table 1. Subjects’ characteristics

<table>
<thead>
<tr>
<th>Age, yr</th>
<th>15G</th>
<th>15G + LEU</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>69 ± 2</td>
<td>66 ± 2</td>
<td>0.45</td>
<td></td>
</tr>
<tr>
<td>Total body mass, kg</td>
<td>78.8 ± 3.2</td>
<td>79.0 ± 2.4</td>
<td>0.96</td>
</tr>
<tr>
<td>Total lean mass, kg</td>
<td>57.6 ± 2.3</td>
<td>58.1 ± 1.5</td>
<td>0.86</td>
</tr>
<tr>
<td>Appendicular lean mass, kg</td>
<td>24.9 ± 1.1</td>
<td>25.6 ± 0.7</td>
<td>0.64</td>
</tr>
<tr>
<td>Percent body fat, %</td>
<td>23.9 ± 0.9</td>
<td>23.2 ± 1.2</td>
<td>0.62</td>
</tr>
<tr>
<td>Height, m</td>
<td>1.75 ± 0.02</td>
<td>1.78 ± 0.01</td>
<td>0.23</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>25.8 ± 0.8</td>
<td>24.9 ± 0.8</td>
<td>0.43</td>
</tr>
<tr>
<td>HDL-C, %</td>
<td>5.3 ± 0.1</td>
<td>5.3 ± 0.1</td>
<td>0.80</td>
</tr>
<tr>
<td>RSG, mmol/l</td>
<td>5.8 ± 0.2</td>
<td>6.2 ± 0.2</td>
<td>0.13</td>
</tr>
<tr>
<td>Resting insulin, μU/l</td>
<td>9.3 ± 0.9</td>
<td>8.4 ± 1.2</td>
<td>0.59</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>2.4 ± 0.2</td>
<td>2.4 ± 0.4</td>
<td>1.00</td>
</tr>
<tr>
<td>MVPa, min</td>
<td>145 ± 31</td>
<td>160 ± 33</td>
<td>0.95</td>
</tr>
<tr>
<td>1RM - leg press, kg</td>
<td>179 ± 8</td>
<td>166 ± 6</td>
<td>0.23</td>
</tr>
<tr>
<td>1RM - leg extension, kg</td>
<td>86 ± 6</td>
<td>88 ± 2</td>
<td>0.79</td>
</tr>
<tr>
<td>1RM - lat pulldown, kg</td>
<td>60 ± 4</td>
<td>62 ± 4</td>
<td>0.78</td>
</tr>
<tr>
<td>1RM - chest press, kg</td>
<td>60 ± 6</td>
<td>58 ± 5</td>
<td>0.77</td>
</tr>
</tbody>
</table>

Values are means ± SE; n = 12 per treatment group. 15G, 15 g of dietary protein; 15G + LEU, 15 g dietary protein +1.5 g of free crystalline leucine; HOMA-IR, homeostasis model assessment of insulin resistance; 1RM, one repetition maximum; HbA1c, glycated hemoglobin; MVPa, moderate-to-vigorous physical activity; Resting, resting and fasted values. Data were analyzed with Student’s unpaired t-test. No differences were detected between groups.
performed using a calibrated IVAC 598 pump (San Diego, CA). Intrinsically L-[1-13C]phenylalanine- and L-[1-13C]leucine-labeled milk protein (MPC80) was extracted from whole milk obtained during the constant infusion of L-[1-13C]phenylalanine (455 μmol/min) and L-[1-13C]leucine (200 μmol/min) for 96 h in a lactating dairy cow (8, 44). The milk was collected, processed, and fractionated into the MPC80 similarly to what has been previously described (19, 37, 44). The L-[1-13C]phenylalanine and L-[1-13C]leucine enrichments in MPC80 were measured by gas chromatography-combustion-isotope ratio mass spectrometry (GC-IRMS; MAT 252; Finnigan, Breman, Germany) and averaged 38.3 mole percent excess (MPE) and 10.8 MPE, respectively. The proteins met all chemical and bacteriological specifications for human consumption.

**Plasma and muscle analysis.** Plasma glucose and insulin concentrations were analyzed using commercially available kits (GLUC3, Roche, Ref. 05168791 190; and Immunologic, Roche, Ref. 12017547 122, respectively). Plasma amino acid concentrations and enrichments were determined by gas chromatography-mass spectrometry analysis (GC-MS; Agilent 7890A GC/5975C; MSD, Wilmington, DE). Myofibrillar protein-bound L-[ring-2H5]phenylalanine enrichments were determined by GC-MS analysis, whereas the L-[1-13C]phenylalanine and L-[1-13C]leucine enrichments were determined by

| Table 2. Amino acid composition of test beverages |
|----------------|----------------|
|                | 15G            | 15G+LEU       |
| Alanine        | 0.45           | 0.45          |
| Arginine       | 0.50           | 0.50          |
| Aspartic acid  | 0.92           | 0.92          |
| Glutamic acid  | 2.51           | 2.51          |
| Glycine        | 0.23           | 0.23          |
| Histidine      | 0.33           | 0.33          |
| Isoleucine     | 0.66           | 0.66          |
| Leucine        | 1.44           | 2.94          |
| Lysine         | 1.19           | 1.19          |
| Methionine     | 0.18           | 0.18          |
| Phenylalanine  | 0.63           | 0.63          |
| Proline        | 1.38           | 1.38          |
| Serine         | 0.70           | 0.70          |
| Threonine      | 0.57           | 0.57          |
| Tyrosine       | 0.78           | 0.78          |
| Valine         | 0.84           | 0.84          |

Values are expressed in g. 15G, 15 g of dietary protein; 15G+LEU, 15 g of dietary protein + 1.5 g of free crystalline leucine.

(3.6 μmol/kg), L-[ring-2H2]tyrosine (1.10 μmol/kg), and L-[1-13C]leucine (7.19 μmol/kg). Once primed, the continuous stable isotope infusion was initiated (infusion rates: 0.06 μmol·kg⁻¹·min⁻¹ L-[ring-2H2]phenylalanine, 0.018 μmol·kg⁻¹·min⁻¹ L-[ring-2H2]tyrosine, and 0.12 μmol·kg⁻¹·min⁻¹ L-[1-13C]leucine; Cambridge Isotope Laboratories, Andover, MA). Participants rested for 1.5 h until 1000 (t = 0 min), when the participants completed the resistance-type exercise session. At 1100 (t = 0 min), immediately after the resistance-type exercise session, subjects had a blood sample and muscle biopsy collected from a randomized leg. Subsequently, subjects ingested a 500-ml beverage containing 15 g of intrinsically L-[1-13C]phenylalanine- and L-[1-13C]leucine-labeled milk protein (MPC80) alone (15G) or with an added 1.5 g of crystalline free leucine (15G+LEU) (Table 2). The beverages contained 1.5 ml of vanilla extract to improve palatability (Dr. Oetker, Amersfoort, The Netherlands).

Blood samples (10 ml) were subsequently taken at t = 30, 60, 90, 120, 180, 240, 300, and 360 min after protein ingestion. A second muscle biopsy was obtained from the contralateral leg at 1700 (t = 360 min), signifying the end of the experimental trial.

Blood samples were collected in EDTA-containing tubes and centrifuged at 1,000 g for 10 min at 4°C. Aliquots of plasma were frozen in liquid nitrogen and stored at −80°C. Muscle biopsies were obtained from the middle region of the vastus lateralis muscle 15 cm above the patella and ~4 cm below entry through the fascia, using the percutaneous needle biopsy technique (5). Muscle samples were dissected carefully and freed from any visible nonmuscle material. The muscle samples were immediately frozen in liquid nitrogen and stored at −80°C until further analysis.

**Resistance-type exercise protocol.** The exercise protocol consisted of 60 min of moderate-to-high intensity whole-body resistance-type exercise. After 10 min of self-paced cycling at 100 W with a cadence of 60–80 RPM, subjects performed 5 sets of 10 repetitions on the horizontal leg press machine (Technogym BV, Rotterdam, Netherlands), 2 sets of 10 repetitions on the lat pull down machine (Technogym BV), 2 sets of 10 repetitions on the chest press machine and 5 sets of 10 repetitions on the leg extension machine (Technogym). The first set of the lower body exercises were performed at 50% 1RM and sets 2–5 were performed at 75–80% 1RM. All sets on the upper body exercises were performed at 75–80% 1RM. Subjects were allowed to rest for 2 min between all sets.

**Preparation of tracer and production of intrinsically labeled protein.** The stable isotope tracers L-[ring-2H5]phenylalanine, L-[1-13C]leucine, and L-[ring-2H2]tyrosine were purchased from Cambridge Isotopes and dissolved in 0.9% saline before infusion (Basic Pharma, Geleen, The Netherlands). Continuous intravenous infusions were
Western blotting. Muscle was homogenized as previously described (46), 10 μl of protein was loaded, and standard SDS-PAGE procedures were followed. Antibodies included total and phosphorylated mTOR (cat. nos. Total: 2972, Ser2448: 2971), S6K1 (cat. nos. Total: 9202, Thr389, 9205), RS6 (cat. nos. Total: 2217, Ser235/236, 4856), eukaryotic initiation factor 4E-binding protein-1 (4E-BP1; cat. nos. Total: 9452, Thr37/46, 9459), α-tubulin (cat. no. 2125) was used as a loading control. All antibodies were purchased from Cell Signaling Technology (Danvers, MA). All samples for a given protein were detected on the same membrane using chemiluminescence and the FluorChem HD imaging system (Alpha Innotech, Santa Clara, CA).

Calculations. Ingestion of l-[1-13C]phenylalanine-labeled protein, intravenous infusion of l-[ring-2H5]phenylalanine, and blood sample enrichment values were used to assess whole body amino acid kinetics in non-steady-state conditions. Total, exogenous, and endogenous phenylalanine rates of appearance and plasma availability of dietary protein-derived phenylalanine that appeared in the systemic circulation as a fraction of total amount of phenylalanine that was ingested, (Phenplasma) were calculated using modified Steele’s equations (6, 11, 52). Myofibrillar protein fractional synthetic rate (FSR) was calculated using the standard precursor-product method (Eq. 1).

$$\text{FSR} \text{(% h}^{-1} ) = \left( \frac{E_{m2} - E_{m1}}{E_{\text{precursor} \times t}} \right) \times 100$$  \tag{1}

$E_{m2} - E_{m1}$ represents the change in muscle protein bound l-[1-13C]leucine or l-[ring-2H5]phenylalanine enrichment. $E_{\text{precursor}}$ represents the average plasma l-[1-13C]leucine or l-[ring-2H5]phenylalanine enrichment during the tracer incorporation period; $t$ indicates the time interval (h) between biopsies.

Statistics. Data are expressed as means ± SE or as box-whisker plots. Baseline characteristics between groups were compared using Student’s unpaired t-test. A two-factor repeated-measures ANOVA (time × treatment) with time as within-subjects factor and treatment group as between-subjects factor was performed for the analysis of plasma amino acid concentrations, plasma tracer enrichments, whole body kinetics, and glucose and insulin concentrations. The analysis was carried out for the period starting at the time of protein administration, between $t = 0$ and 360 min. Upon identification of a significant time × treatment interaction, Tukey’s post hoc testing was used to identify time points in which the treatments differed. Non-time-dependent variables (i.e., whole body metabolism, FSR values, l-[1-13C]phenylalanine myofibrillar enrichments) were compared between treatment groups using Student’s unpaired t-tests. Statistical significance was set at $P < 0.05$. All calculations were performed using SPSS 21.0 (IBM, Chicago, IL).

Fig. 2. Plasma leucine (A), phenylalanine (C), and tyrosine (D) concentrations (μmol/l) following ingestion of 15 g of milk protein (15G; $n = 12$) or 15 g of milk protein coingested with 1.5 g of free leucine (15G+LEU; $n = 12$) during recovery from resistance-type exercise in older men. Dotted line represents ingestion of the beverage. Values for A, C, and D represent means ± SE. Data were analyzed with repeated-measures (time × treatment group) ANOVA. A: time effect, $P < 0.01$; treatment effect, $P < 0.01$; time × treatment group, $P < 0.01$. C: time effect, $P < 0.01$; treatment effect, $P < 0.01$; time × treatment group, $P > 0.05$. D: time effect, $P < 0.01$; treatment effect, $P < 0.01$; time × treatment group, $P > 0.05$. Plasma leucine area under the curves over 360 min ($B$, μmol·360 min$^{-1}$) are presented as box and whisker plots. Boxes represent 25th to 75th percentiles. Horizontal lines and crosses within boxes represent medians and means, respectively. Whiskers represent minimum and maximum values. Data were analyzed with Student’s unpaired t-test. *Significant difference ($P < 0.05$) from 15G.
RESULTS

**Plasma concentrations.** Plasma glucose (Fig. 1A) and insulin (Fig. 1B) concentrations after protein ingestion did not differ between the 15G and 15G+LEU groups (P > 0.05). Plasma insulin concentrations increased after protein ingestion in both treatments, reaching peak levels 30 min after protein ingestion.

Plasma leucine concentrations (Fig. 2A) increased rapidly following protein ingestion (P < 0.01) but were greater in 15G+LEU (peak values 407 ± 23 μmol/l) compared with 15G (peak values 234 ± 16 μmol/l, P < 0.01). Area under the curve (AUC; Fig. 2B) analysis revealed that plasma leucine availability over the 6-h postprandial was ~1.8-fold greater in the 15G+LEU group compared with the 15G group (P < 0.001). Plasma phenylalanine concentrations (Fig. 2C) increased rapidly following protein ingestion (time effect, P < 0.01) along with a main effect for treatment (treatment effect, P < 0.01), but no time × treatment interaction (P > 0.05).

Plasma tyrosine concentrations (Fig. 2D) increased following protein ingestion (time effect, P < 0.01) along with a main effect for treatment (treatment effect, P < 0.01) but no time × treatment interaction (P > 0.05).

**Plasma amino acid enrichments.** Plasma enrichments from ingested (l-[1-13C]phenylalanine), infused (l-[ring-2H5]phenylalanine), and ingested and infused (l-[1-13C]leucine) amino acid tracers did not differ between treatments before protein ingestion (t = 0 min, P > 0.05). After protein ingestion, plasma l-[1-13C]phenylalanine enrichments, originating from the ingested protein, increased in both groups, reaching peak values at t = 60 min in 15G (9.6 ± 0.5 MPE) and t = 120 min in 15G+LEU (8.7 ± 0.5 MPE) in 15G+LEU. Plasma l-[ring-2H5]phenylalanine enrichments decreased after protein ingestion in both groups (P < 0.001), but no significant group effect was detected (P > 0.05). Plasma l-[1-13C]leucine enrichments increased after protein ingestion (P < 0.001), but no significant group effects were detected (P > 0.05).

**Whole body amino acid kinetics.** Exogenous phenylalanine appearance rates (Fig. 3A) increased following protein ingestion, with peak levels being reached at t = 60 min in both treatment groups (15G, 0.19 ± 0.01; 15G+LEU, 0.16 ± 0.02 μmol Phe·kg⁻¹·min⁻¹, P > 0.05). Dietary protein-derived amino acid availability, calculated as a fraction of the total amount of ingested protein (Fig. 3B), was higher in 15G (75 ± 2%) than in 15G+LEU (70 ± 1%, P < 0.05).

Whole body protein synthesis rates did not differ between the treatment groups (15G, 0.60 ± 0.01; 15G+LEU, 0.59 ± 0.01 μmol Phe·kg⁻¹·min⁻¹, P > 0.05). Whole body protein breakdown rates did not differ between the treatment groups (15G, 0.49 ± 0.01; 15G+LEU, 0.49 ± 0.01 μmol Phe·kg⁻¹·min⁻¹, P > 0.05). Protein ingestion resulted in a positive whole body protein net balance, with no differences observed between the treatment groups (15G, 0.108 ± 0.004; 15G+LEU, 0.105 ± 0.003 μmol Phe·kg⁻¹·min⁻¹, P > 0.05). Furthermore, leucine coingestion did not appear to influence whole body phenylalanine oxidation rates (15G, 0.049 ± 0.003; 15G+LEU, 0.046 ± 0.002 μmol Phe·kg⁻¹·min⁻¹, P > 0.05).

**Myofibrillar FSRs and protein-bound enrichments.** Myofibrillar l-[1-13C]leucine and l-[ring-2H5]phenylalanine enrichments were measured in muscle samples collected immediately before protein ingestion and after the 6-h postprandial period. The postprandial increase in myofibrillar protein-bound l-[1-13C]leucine enrichments tended to be greater in 15G+LEU than in 15G (0.0360 ± 0.0016 vs. 0.0314 ± 0.0016 MPE, respectively, P = 0.055). The postprandial increase in myofibrillar protein-bound l-[ring-2H5]phenylalanine enrichment was greater in 15G+LEU than in 15G (0.0330 ± 0.0015 vs. 0.0278 ± 0.0011 MPE, respectively, P < 0.05).

Myofibrillar protein FSRs (in %/h) were calculated using l-[ring-2H5]phenylalanine plasma (Fig. 4A) and muscle protein-bound enrichments and using l-[1-13C]leucine (Fig. 4B) plasma and muscle protein-bound enrichments. When based on l-[ring-2H5]phenylalanine, myofibrillar protein FSR was ~16% greater in 15G+LEU (0.0575 ± 0.0032%/h) than in 15G (0.0495 ± 0.0021%/h, P < 0.05). When based on l-[1-13C]leucine, myofibrillar protein FSR was ~19% greater in 15G+LEU (0.0710 ± 0.0048%/h) than in 15G (0.0598 ± 0.0030%/h, P < 0.05). l-[1-13C]phenylalanine myofibrillar protein-bound enrichments (Fig. 5) were not different in

---

**Fig. 3.** Exogenous phenylalanine rate of appearance (Ra) (A, μmol Phe·kg⁻¹·min⁻¹) following ingestion of 15 g of milk protein (15G; n = 12) or 15 g of milk protein coingested with 1.5 g of free leucine (15G+LEU; n = 12) during recovery from resistance-type exercise in older men. Dotted line represents ingestion of the beverage. Values for A represent means ± SE. Data were analyzed with repeated-measures (time × treatment group) ANOVA. A: time effect, P < 0.01; treatment effect, P < 0.05; time × treatment group, P > 0.05. Dietary protein-derived amino acid plasma availability (B), calculated as a fraction of the total amount of ingested protein (% ingested protein), are presented as box and whisker plots. Boxes represent 25th to 75th percentiles. Horizontal lines and crosses within boxes represent medians and means, respectively. Whiskers represent minimum and maximum values. Data were analyzed with Student’s unpaired t-test. *Significantly different (P < 0.05) from 15G.
15G+LEU (0.0205 ± 0.0022 MPE) compared with 15G (0.0171 ± 0.0017 MPE, \( P = 0.24 \)).

**Cellular signaling analyses.** The phosphorylation status (ratio of phosphorylated to total protein) of key proteins involved in the initiation of muscle protein synthesis are presented in Fig. 6. Phosphorylation of S6K1 (Fig. 6B) decreased in both groups over time (time effect, \( P < 0.01 \)). Phosphorylation of 4E-BP1 (Fig. 6D) increased over time and to a greater extent in 15G compared with 15G+LEU (\( P < 0.01 \)).

**DISCUSSION**

In the present study, we examined the impact of free leucine coingestion on postprandial protein handling and the subsequent muscle protein synthetic response following the ingestion of 15 g of protein during recovery from resistance-type exercise in older men. We observed that 70–75% of the dietary-derived amino acids was absorbed into the circulation over the 6-h postprandial period (10.5 ± 0.2 vs. 11.2 ± 0.3 g, \( P < 0.05 \)). This was attributed to a mild attenuation of exogenous amino acid appearance rates observed between 30 and 120 min (Fig. 3A). It could be speculated that the added free leucine might have stimulated splanchnic amino acid retention of dietary-protein derived amino acids during first pass. In agreement, prior work in neonatal pigs has demonstrated that free leucine coingested with a low protein dose stimulates an increase in jejunum, but not liver, protein synthesis (29, 39). All together, our data demonstrate that free much more compared with recent work from our laboratory using the same methodology (21, 34, 35). The apparent discrepancy is attributed to the relatively small amount of dietary protein that was provided in the present study along with the extended 6-h postprandial assessment period, implying that more protein-derived amino acids will be absorbed during such an extended postprandial period with a relatively smaller bolus of protein being ingested (22). Free leucine fortification seemed to compromise protein digestion and/or amino acid absorption, as dietary protein-derived phenylalanine availability was lower following leucine coingestion when assessed over the entire 6-h postprandial period (10.5 ± 0.2 vs. 11.2 ± 0.3 g, \( P < 0.05 \)).
leucine coingestion further increases the postprandial rise in leucine concentrations but attenuates the rate of appearance of dietary protein-derived amino acids into the circulation.

By administering a primed, continuous intravenous infusion of L-\([\text{ring-}^2\text{H}_5]\)phenylalanine and L-\([\text{ring-}^2\text{H}_2]\)tyrosine and providing intrinsically L-[1-\(13\text{C}\)]phenylalanine-labeled protein, we were able to assess postprandial whole body protein synthesis, breakdown, net balance, and oxidation. In both groups, protein ingestion resulted in a positive whole body net protein balance during postexercise recovery. However, fortification with free leucine did not further impact whole body postprandial protein synthesis, breakdown, or net balance. These findings are in agreement with prior work in older men at rest (38) and in younger men during postexercise recovery (25). Despite previous reports that leucine administration lowers whole body amino acid oxidation rates (24, 32), we did not observe this effect. These studies achieved far greater plasma leucine availability compared with the present study, which may lead to a reduction in protein breakdown rates (32, 42), thereby lowering the availability of amino acids for oxidation (25, 42). Our present data align with recent work administering similar, meal-like amounts of leucine (~4.5 g total) (38), and demonstrate that leucine coingestion does not impact whole body phenylalanine oxidation rates.

Changes in whole body protein metabolism do not necessarily reflect changes on a muscle tissue level. Therefore, we also collected skeletal muscle biopsies to directly assess the impact of leucine fortification of a low-protein dose on intramuscular signaling and the muscle protein synthetic response to feeding. Resistance-type exercise and protein ingestion activate intramuscular signaling proteins that regulate protein translation, with mTOR and its downstream targets S6K1, RS6, and 4E-BP1 being of particular relevance. We observed no differences in mTOR or RS6 phosphorylation, but we detected a decrease in S6K1 phosphorylation over time. These findings align with previous work showing a rapid increase in S6K1 activity following exercise, which subsides over 3–6 h (26, 51). Considering that biopsy timing was intended to assess the muscle protein synthetic response during the entire postprandial period, it is most likely that transient increases in signaling activity had subsided by 6 h. However, 4E-BP1 phosphorylation increased over time in both groups, and to a greater extent after the ingestion of 15 g of protein compared with the ingestion of 15 g with leucine. We speculate that the

---

**Fig. 6.** Muscle phosphorylation (Phos) status [ratio of phosphorylated to total protein, arbitrary unit (AU)] of mammalian target of rapamycin (mTOR; A) S6 protein kinase-1 (S6K1; B), ribosomal protein S6 (RS6; C), and eukaryotic translation initiation factor 4E-binding protein-1 (4E-BP1; D) in older men during recovery from resistance-type exercise (0 min) and 360 min after ingestion of 15 g of milk protein (15G; \(n = 12\)) or 15 g of milk protein coingested with 1.5 g of free leucine (15G+LEU; \(n = 12\)). Boxes represent 25th to 75th percentiles. Horizontal lines and crosses within boxes represent medians and means, respectively. Whiskers represent minimum and maximum values. Data were analyzed with repeated-measures (time \times treatment group) ANOVA. A: time effect, \(P < 0.05\); treatment effect, \(P < 0.05\); time \times treatment group, \(P > 0.05\). B: time effect, \(P < 0.01\); treatment effect, \(P < 0.05\); time \times treatment group, \(P > 0.05\). C: time effect, \(P > 0.05\); treatment effect, \(P > 0.05\); time \times treatment group, \(P > 0.05\). D: time effect, \(P < 0.01\); treatment effect, \(P > 0.01\); time \times treatment group, \(P < 0.01\). *Significantly different \((P < 0.05)\) compared with \(t = 0\) min; †significantly different \((P < 0.05)\) from 15G+LEU at the same time point.
higher leucine availability in 15G+LEU may have transiently activated 4E-BP1 at an earlier time compared with 15G (14, 18, 23), which steadily activated 4E-BP1 over the 6-h postprandial period (26, 49).

Combining stable-isotope-labeled amino acid infusions with ingestion of intrinsically labeled protein, we were able to assess muscle protein synthesis rates under both steady-state (L-[1-13C]leucine) as well as non-steady-state (L-[ring-2H5]phenylalanine) precursor conditions (8). Previous work has demonstrated that the ingestion of a low-protein dose (<20 g) following resistance-type exercise does not further stimulate an increase in muscle protein synthesis rates in older individuals (53, 54). In the present study, free leucine coingested with a low-protein dose (15 g) increased myofibrillar protein synthesis rates by 16% (L-[ring-2H5]phenylalanine, Fig. 4A) and 19% (L-[1-13C]leucine, Fig. 4B) compared with the ingestion of 15 g of protein. These findings are in line with multiple studies demonstrating that free leucine coingestion can further increase the muscle protein synthetic response to protein ingestion in older individuals at rest (2, 9, 12, 13, 30) and during recovery from resistance-type exercise (2, 7, 9, 12, 13, 30). In the present study, participants ingested intrinsically labeled milk protein. These findings are in line with multiple studies demonstrating that free leucine coingestion can further increase the muscle protein synthetic response to protein ingestion in older individuals at rest (2, 9, 12, 13, 30) and during recovery from resistance-type exercise (2, 7, 9, 12, 13, 30).

In conclusion, leucine coingestion further augments the postexercise muscle protein synthetic response to the ingestion of a small amount of protein in older men.

30 g of MPC80. Therefore, increasing the leucine content of meal consumed may increase the efficiency by which the ingestion of smaller protein doses can augment muscle protein synthesis rates during recovery from exercise. Simply adding leucine to a postexercise snack to achieve ~3 g total leucine, may represent an effective strategy to support muscle mass maintenance in the older population without the need to ingest large(r) doses of protein. So far only few long-term intervention studies have assessed the anabolic effect of prolonged leucine supplementation. Whereas prolonged leucine supplementation does not seem to increase muscle mass in older individuals (27, 45), it has been suggested that leucine supplementation may augment muscle mass when combined with prolonged resistance-type exercise training (43). Nonetheless, more work is needed to assess the long-term benefits of leucine supplementation in combination with prolonged resistance-type exercise training in the older population.

In conclusion, leucine coingestion further augments the postexercise muscle protein synthetic response to the ingestion of a small amount of protein in older men.

REFERENCES


